Hanmi Pharma Prices Obesity Drug 50% Below Rivals; Citi Sees Bank of Korea Hawkish Hold

The Quick Take

• Hanmi Pharmaceutical's epeglenatide obesity drug (Efpe) is expected to cost approximately 120,000 KRW monthly initially—over 50% below Eli Lilly's Mounjaro on a per-dose basis
• Citi Research forecasts the Bank of Korea will hold its benchmark rate at 3.00% in October with a hawkish tone, projecting further hikes toward a 3.50% terminal rate by February 2027
• South Korea's Financial Supervisory Service is expanding whistleblower protections in savings banks and mutual finance, raising maximum reward payouts to 1 billion KRW

South Korea's pharmaceutical sector is entering the global GLP-1 obesity drug market with a competitive pricing strategy. Hanmi Pharmaceutical's epeglenatide, approved by Korea's drug regulator on October 7, uses the company's proprietary LAPSCOVERY long-acting platform technology. The drug enters a market currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, and its pricing at more than 50% below competitors at initiation doses positions it as a cost-accessible alternative. Lower pricing could accelerate domestic patient adoption and create a reference price that complicates premium pricing strategies for multinational GLP-1 competitors in other Asia-Pacific markets.

Hanmi Pharmaceutical's aggressive pricing creates competitive pressure on Novo Nordisk and Eli Lilly in the Korean and potentially broader Asian obesity drug market. On the monetary policy front, Citi's hawkish-hold forecast for the Bank of Korea's October 22 meeting—with rate hikes projected through February—implies continued pressure on Korean borrowing costs, financial sector net interest dynamics, and household credit affordability. The FSS whistleblower reform at savings banks and mutual finance institutions introduces near-term compliance costs but reduces longer-term fraud risk, which is structurally positive for institutional credit quality in Korea's smaller financial sector.

Key forward signals include Hanmi Pharmaceutical's official epeglenatide launch announcement and early sales data confirming whether pricing translates to volume uptake. The Bank of Korea's October 22 monetary policy committee vote will confirm or revise Citi's hawkish-hold call, with attention on dissenting votes favoring immediate rate action. Implementation timelines for the FSS whistleblower framework will clarify compliance investment requirements across Korea's savings bank sector, while Hanmi's licensing agreements for LAPSCOVERY internationally may yield additional revenue disclosure in upcoming investor communications.

Synthesized from 4 sources.